Day: May 25, 2023

Oslo, Norway, 25 May– IDEX Biometrics and SELP, a French card manufacturer and personalization center with a global footprint, are entering an agreement to scale the deployment of biometric smart cards, in response to growing demand for secure and convenient payment and identification solutions. With an annual card production of more than 350 million and servicing over 60 countries across Europe, Central America, Africa, the Middle East, and India, SELP is uniquely positioned to drive the commercialization of biometric technology across a wide range of sectors including payments, digital ID, digital services, and retail. “This agreement enables us to strengthen the ecosystem and meet the increasing demand for seamless payment and identification experiences,” said Bastien Blanc, General Manager of SELP. “By working with IDEX Biometrics,...

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:Redeye Growth Day Virtual, June 1, 2023 Mendus CEO Erik Manting will participate in a live Q&A session on June 1st. Further details including the on-demand corporate presentation are available via:https://www.redeye.se/events/871323/redeye-growth-dayBIO International Convention Boston, USA, June 5-8, 2023 Erik Manting, CEO of Mendus, will attend the conference. https://www.bio.org/events/bio-international-conventionEHA2023 Hybrid Congress Frankfurt, Germany, and Virtual, June 8-11, 2023 Mendus to present updates on immunomonitoring data from ADVANCE II trial and progress on the development of its NK cell therapy program. https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/FOR...

Atari launches an offering of bonds convertible into new ordinary shares of Atari maturing in 2026 with a 6.50% coupon for a nominal amount of approximately 30 million eurosIssuance of bonds convertible into ordinary shares without shareholders’ preferential subscription rights, by way of a public offering and with a four-day priority subscription period, on an irreducible and reducible basis Public subscription period and priority subscription period: from May 25, 2023 to May 30, 2023 (included) at 5:00 p.m. (Paris time) Subscription price set at 0.15 euro per convertible bond Subscription commitment of Irata LLC to subscribe for 100% of the Offering Key financial information as of March 31, 2023PARIS, FRANCE (May 25, 2023 – 7:45 am CET) – Atari® (the “Company”) — one of the world’s most iconic...

Ecully, May 25th, 2023 PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC CorporationPCAS (Euronext Paris: PCA), specialized in the development of processes and production of complex molecules for Life Sciences and Specialty Chemicals Markets, has made the decision to sell PCAS Canada Inc., the Canadian subsidiary of PCAS Group, to DIC Corporation, a Japanese chemicals group with a presence in more than 60 countries. An enterprise value of 88.2 million euros has been agreed for PCAS Canada Inc. This decision has been made following the receipt of an offer from DIC Corporation for the acquisition of the Canadian subsidiary announced on May 2nd, 2023 (https://www.pcas.com/). This offer has been accepted by PCAS following the authorization of its Board of Directors. The competent workers’ council has been previously informed...

Letter to Shareholders and Corporate UpdateAccess to EUR15 million under amended deal Donesta® U.S. marketing deal is a key near term priority CDMO strategic options are being explored Donesta® filing rescheduled for H2 2023 – still expecting U.S. approval in H1 2024 Financial update and guidance providedLiege, Belgium, 25 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”), today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. David Horn Solomon. Dear Fellow Shareholders, I am pleased to have joined Mithra as CEO on April 11th. I was made fully aware of the Company’s recent challenges and the many justified concerns of our shareholders. I accepted the role because my...

Letter to Shareholders and Corporate UpdateAccess to EUR15 million under amended deal Donesta® U.S. marketing deal is a key near term priority CDMO strategic options are being explored Donesta® filing rescheduled for H2 2023 – still expecting U.S. approval in H1 2024 Financial update and guidance providedLiege, Belgium, 25 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”), today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. David Horn Solomon. Dear Fellow Shareholders, I am pleased to have joined Mithra as CEO on April 11th. I was made fully aware of the Company’s recent challenges and the many justified concerns of our shareholders. I accepted the role because my analysis...

SAMPO PLC                 STOCK EXCHANGE RELEASE         25/05/2023 at 08:30 am Sampo plc’s share buybacks 24/05/2023 On 24/05/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  8,600 43.03 AQEU  27,539 43.02 CEUX  12,722 43.04 TQEX  71,139 43.02 XHELTOTAL 120,000 43.02  *rounded to two decimals                 On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is...

SECURITIES NOTE This securities note (the “Securities Note”) is made available in connection with the offer of bonds convertible into new shares, without subscription rights and with a priority subscription period (délai de priorité), on an irreducible and reducible basis, for a gross amount of 30 million euros by issuing 200,000,000 convertible bonds at a price of 0.15 euro each to be subscribed in cash and / or by debt set-off.AttachmentArcade – Securities Note – VF (2)

Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2Sandoz continues to build its biosimilars portfolio to increase patient access to high-quality, affordable biologics and generate savings for health systemsBasel, May 25, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Medicines Agency (EMA) has accepted the marketing authorization applications (MAA) for proposed biosimilar denosumab for regulatory review. The...